A low level of high density lipoprotein cholesterol (HDL-C) is an independent risk factor for coronary heart disease (CHD). It is estimated that more than 50% of the variation in HDL-C levels in humans is genetically determined. There is great interest in the concept that common genetic variants contribute to inherited differences in the susceptibility to common diseases. One promising approach to address this issue is to relate variation in DNA sequence with patient characteristics in population-based association studies. We are proposing to identify allelic variants associated with the low HDL trait, using samples from the Veterans Affairs HDL Intervention Trial (VA-HIT, cases), a study designed to explore the benefits of HDL-raising with gemfibrozil in men having low HDL-C (<40 mg/dL), normal LDL-C (<140 mg/dL) and known CHD, and the Framingham Offspring Study (FOS, controls). Our primary aims are to identify: 1) susceptibility loci for the low HDL trait, 2) allelic variants associated with levels of apolipoproteinA-l-containing HDL subspecies, and 3) allelic variants associated with response to gemfibrozil in VA-HIT.
For Aim 1, we will examine biological (n=38) and positional (n=3) candidates. The former will include genes involved in HDL metabolism, insulin resistance and inflammation, while the latter will be selected on the basis of results from genome-wide linkage scans for quantitative trait loci associated with HDL-C levels in FOS. For each candidate, we will use HapMap data in order to select a maximally informative set of SNPs (tagSNPs), which will allow us to resolve >80% of all haplotypes. Based on this algorithm, we will genotype 1 SNP per 2500 bp across each candidate gene/region. To address the issue of population stratification, we will employ a structured association approach, using a set of 250 markers that has the ability to detect modest amounts of stratification. The results of this work will provide important insight into the contribution of allelic variation in the pathways of HDL metabolism, inflammation, and insulin resistance to the complex phenotype of low HDL-C.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL060935-04A2
Application #
6926809
Study Section
Epidemiology of Chronic Diseases Study Section (ECD)
Program Officer
Ershow, Abby
Project Start
1999-04-01
Project End
2009-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
4
Fiscal Year
2005
Total Cost
$316,952
Indirect Cost
Name
Tufts University
Department
Type
Organized Research Units
DUNS #
039318308
City
Boston
State
MA
Country
United States
Zip Code
02111
Anthanont, Pimjai; Polisecki, Eliana; Asztalos, Bela F et al. (2014) A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production. Atherosclerosis 235:470-6
Dimick, Susan M; Sallee, Brigitte; Asztalos, Bela F et al. (2014) A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy. J Clin Lipidol 8:223-30
Schaefer, Ernst J; Anthanont, Pimjai; Asztalos, Bela F (2014) High-density lipoprotein metabolism, composition, function, and deficiency. Curr Opin Lipidol 25:194-9
Thongtang, Nuntakorn; Diffenderfer, Margaret R; Ooi, Esther M M et al. (2013) Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis 226:466-70
Lee, Esther Y; Klementowicz, Peter T; Hegele, Robert A et al. (2013) HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. J Clin Lipidol 7:169-73
Thongtang, Nuntakorn; Diffenderfer, Margaret R; Ooi, Esther M M et al. (2013) Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism 62:369-75
Thongtang, Nuntakorn; Lin, Jianxin; Schaefer, Ernst J et al. (2012) Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis 225:388-96
van Himbergen, Thomas M; Beiser, Alexa S; Ai, Masumi et al. (2012) Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study. Arch Neurol 69:594-600
Thongtang, Nuntakorn; Ai, Masumi; Otokozawa, Seiko et al. (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107:387-92
Roshan, Bijan; Ganda, Om P; Desilva, Ranil et al. (2011) Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature. J Clin Lipidol 5:493-9

Showing the most recent 10 out of 36 publications